FDA Recalls PharmaTech Liquid Products for B. cepacia Contamination Risk
On August 10, 2017, FDA announced a voluntary recall of all liquid products manufactured by PharmaTech and distributed by Leader Brand, Major Pharmaceuticals and Rugby Laboratories because of possible Burkholderia cepacia (B. cepacia) contamination.
On August 10, 2017, FDA announced a voluntary recall of all liquid products manufactured by PharmaTech and distributed by Leader Brand, Major Pharmaceuticals and Rugby Laboratories because of possible Burkholderia cepacia (B. cepacia) contamination. The recalled products were distributed nationwide at wholesale and retail facilities including hospitals and pharmacies.
These products, which include various drugs and dietary supplements intended for use in infants and children, have been linked to a PharmaTech-manufactured product connected to severe adverse event reports of B. cepacia infections in patients. After being alerted to the issue by FDA, Rugby Laboratories issued a voluntary recall on August 3, 2017 of Diocto Syrup and Diocto Liquid (docusate sodium solutions). As a precautionary measure based on additional information received from FDA, the three distribution firms are recalling all lots within expiry of all liquid products manufactured by the manufacturing company. The distribution firms have sent out recall letters and arranged for the return of all recalled products.
Consumers, pharmacies, and healthcare facilities that have the recalled product should cease use and report any adverse events.
Source: FDA
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
